SIRT1 inhibition causes oxidative stress and inflammation in patients with coronary artery disease. 2017

Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Coronary artery disease (CAD) is the primary critical cardiovascular event. Endothelial cell and monocyte dysfunction with subsequent extravagant inflammation are the main causes of vessel damage in CAD. Thus, strategies that repress cell death and manage unsuitable pro-inflammatory responses in CAD are potential therapeutic strategies for improving the clinical prognosis of patients with CAD. SIRT1 (Sirtuin 1) plays an important role in regulating cellular physiological processes. SIRT1 is also thought to protect the cardiovascular system by means of its antioxidant, anti-inflammation and anti-apoptosis activities. In the present study, we found that the SIRT1 expression levels were repressed and the acetylated p53 expression levels were enhanced in the monocytes of patients with CAD. LOX-1/oxidative stress was also up-regulated in the monocytes of patients with CAD, thereby increasing pro-apoptotic events and pro-inflammatory responses. We also demonstrated that monocytes from CAD patients caused endothelial adhesion molecule activation and the adherence of monocytes and endothelial cells. Our findings may explain why CAD patients remain at an increased risk of long-term recurrent ischemic events and provide new knowledge regarding the management of clinical CAD patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051127 Scavenger Receptors, Class E A class of oxidized LDL receptors that contain C-type lectin-like extracellular domains. Scavenger Receptors, Class E, Type I,Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1,OLR1 Protein,Oxidized Low-Density Lipoprotein Receptor 1,SR-E Proteins,SR-EI Proteins,Lectin Like Oxidized Low Density Lipoprotein Receptor 1,Oxidized Low Density Lipoprotein Receptor 1,SR EI Proteins

Related Publications

Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
December 2016, Open access Macedonian journal of medical sciences,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
July 1998, The Canadian journal of cardiology,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
November 2012, Annals of human genetics,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
August 2017, Biomarkers in medicine,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
August 2006, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
January 2023, Current pharmaceutical design,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
January 2023, Current topics in medicinal chemistry,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
August 2008, Expert opinion on therapeutic targets,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
May 2001, Clinical chemistry,
Shih-Hung Chan, and Ching-Hsia Hung, and Jhih-Yuan Shih, and Pei-Ming Chu, and Yung-Hsin Cheng, and Huei-Chen Lin, and Kun-Ling Tsai
January 2012, International journal of medical sciences,
Copied contents to your clipboard!